CardioSCOPE Comprehensive and personalized assessment of acute coronary syndrome by multiomic approach and artificial intelligence strategy
- Coordinator
- Universita Degli Studi Di Milano, Italy
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €1.5m
- Total cost
- —
- Partners
- 12 organisations in 6 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101086397
What the project is doing
In the project's own words, from its summary on CORDIS.
The CardioSCOPE proposal aims to bring together experts from Companies and Αcademia throughout Europe to exchange and expand their expertise on interdisciplinary approaches, to enhance the Research and Innovation capacity of Europe in the field of cardiovascular diseases. Connecting and expanding Europe-wide biobanks and expertise through a comprehensive multiomics approach for the discovery of novel pathological players, CardioSCOPE will give deeper insights into acute coronary syndrome (ACS) development and progression towards major adverse cardiovascular events (MACE).
We will use well-defined prospective cohorts to discover and validate novel genomic, transcriptomic, proteomic and metabolomic signatures specific for ACS and MACE, to be combined in multimarker models by machine learning/artificial intelligence algorithms, enabling more accurate ACS diagnosis and MACE prediction. This excellent research network aims at building scientists competent for the upcoming “omics” era by training and knowledge transfer.
Specific research skills not available at home institutions will be acquired through individually designed secondment plans, training schools, webinars and short-term courses. Intersectoral activities will improve entrepreneurial skills of consortium staff and facilitate transformation of scientific breakthroughs into commercially available products/services. CardioSCOPE includes experts with a wide clinical and research experience, access to patients with ACS and the expertise required for achieving set goals.
World-class institutions gathered within this consortium (from 6 countries: 7 academic, 4 companies, 1 hospital) offer specific expertise, state-of-the-art equipment and adequate human resources to address these challenges. In summary, the results of this project will transcend our own scientific interests to enable a transfer of knowledge into a multidisciplinary environment and achieving significant impact on ACS management and policies in Europe.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Milano | Milano | Italy | Coordinator |
| Panepistimio Kritis | Rethimno | Greece | Participant |
| Biosfer Teslab SL | Reus | Spain | Participant |
| Universitat Rovira I Virgili | Tarragona | Spain | Participant |
| B.s.n. Biological Sales Networks.r.l. | Castelleone | Italy | Participant |
| Fondazione Bruno Kessler | Trento | Italy | Participant |
| Multimedica SpA | Milano | Italy | Participant |
| Genetic Lab SRL | Bucharest | Romania | Participant |
| Institute of Cellular Biology and Pathology 'nicolae Simionescu' - Romanian Academy | Bucharest | Romania | Participant |
| Farmaceutski Fakultet Univerziteta U Beogradu | Belgrade | Serbia | Participant |
| Klinicko-Bolnicki Centar Dr Dragisa Misovic-Dedinje | Beograd | Serbia | Participant |
| University of Ulster | Coleraine | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI